TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31934594

Group type: EXPERIMENTAL
Intervention: Subacromial 10-mL 2% lidocaine injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham injection (no contents injected)
Number of subjects: 40
Study: 31934809

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31934829

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) treatment, 88 sessions from January 2008 to April 2014.
Number of subjects: 70
Study: 31934868

Group type: EXPERIMENTAL
Intervention: Patient portal access with a tablet and tutorial, pre- and postuse surveys, in-person semistructured interviews.
Number of subjects: 97
Study: 31934869

Group type: EXPERIMENTAL
Intervention: Coed Twitter support group
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Women-only Twitter support group
Number of subjects: 960

Group type: COMPARATOR
Intervention: Usual quit-smoking care (control)
Number of subjects: 960
Study: 31934886

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing using i-STAT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard laboratory analysis
Number of subjects: 50
Study: 31934936

Group type: EXPERIMENTAL
Intervention: HCV genotype 3 (subtype 3b)
Number of subjects: 997

Group type: COMPARATOR
Intervention: HCV genotype 1
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: HCV genotype 3
Number of subjects: 997
Study: 31935284

Group type: EXPERIMENTAL
Intervention: BEGEV regimen (bendamustine, gemcitabine, vinorelbine) followed by autologous stem cell transplantation (ASCT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ASCT after BEGEV regimen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: BEGEV regimen
Number of subjects: 59
Study: 31935289

Group type: EXPERIMENTAL
Intervention: Maximum tumor diameter measurement
Number of subjects: 0
Study: 31935746

Group type: COMPARATOR
Intervention: Non-invasive forced oscillometry (FOT) using TremoFlo C-100 Airwave System™
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Infants with TTN
Number of subjects: 155
Study: 31936256

Group type: EXPERIMENTAL
Intervention: Questionnaire items addressing Oral Health Locus of Control (OHLOC)
Number of subjects: 0
Study: 31936677

Group type: EXPERIMENTAL
Intervention: Lower level of maladaptive emotion regulation strategies (t1)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Male gender, higher self-efficacy (t1), lower depression (t1), lower performance and school anxiety (t1), lower social-interaction anxiety (t1), lower procrastination (t1)
Number of subjects: 272
Study: 31936897

Group type: EXPERIMENTAL
Intervention: Calcium electroporation (Ca-EP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bleomycin-based electrochemotherapy (ECT)
Number of subjects: 7
Study: 31937118

Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (DWI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional diffusion-weighted imaging (DWI)
Number of subjects: 55
Study: 31937266

Group type: EXPERIMENTAL
Intervention: Non-pneumatic compression stockings
Number of subjects: 15
Study: 31937310

Group type: EXPERIMENTAL
Intervention: Caverstem 1.0 low dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caverstem 1.0 high dose
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Caverstem 2.0
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 31937474

Group type: EXPERIMENTAL
Intervention: CAREN system (8 sessions, twice weekly for 4 weeks)
Number of subjects: 4
Study: 31937616

Group type: EXPERIMENTAL
Intervention: GDC-0084 (45 mg/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GDC-0084 (various doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GDC-0084 (≥45 mg/day)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GDC-0084
Number of subjects: 47
Study: 31937615

Group type: EXPERIMENTAL
Intervention: Ruxolitinib, lenalidomide, and methylprednisolone
Number of subjects: 28
Study: 31938004

Group type: EXPERIMENTAL
Intervention: 7-day H
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31938786

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (reducing fat intake to 20% of energy and increasing fruit, vegetable, and grain intake)
Number of subjects: 1606

Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 1606
Study: 31938892

Group type: EXPERIMENTAL
Intervention: 295.0 ± 8.2 MBq of the novel PET radiopharmaceutical
Number of subjects: 5
Study: 31939531

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
Number of subjects: 0
Study: 31940024

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 33560

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 33560
Study: 31940346

Group type: EXPERIMENTAL
Intervention: SEARCH HTN screening
Number of subjects: 95000

Group type: EXPERIMENTAL
Intervention: SEARCH clinic appointments for HTN+ participants
Number of subjects: 95000

Group type: EXPERIMENTAL
Intervention: Linkage to care for HTN+ participants
Number of subjects: 95000

Group type: EXPERIMENTAL
Intervention: Follow-up care for SEARCH clinic participants
Number of subjects: 95000
Study: 31941468

Group type: EXPERIMENTAL
Intervention: Chilla participation
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Chilla participation among those not prenatally depressed
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Chilla participation among those prenatally depressed
Number of subjects: 786
Study: 31941516

Group type: EXPERIMENTAL
Intervention: Clinical Feedback System (CFS)
Number of subjects: 0
Study: 31941540

Group type: EXPERIMENTAL
Intervention: European Consortium of Lipodystrophies (ECLip) Registry
Number of subjects: 246
Study: 31941657

Group type: EXPERIMENTAL
Intervention: Treatment in the 1970s
Number of subjects: 23462

Group type: EXPERIMENTAL
Intervention: Treatment in the 1980s
Number of subjects: 23462

Group type: EXPERIMENTAL
Intervention: Treatment in the 1990s
Number of subjects: 23462
Study: 31941953

Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY) treatment
Number of subjects: 135
Study: 31942173

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg once daily for 2 years
Number of subjects: 254

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily for 2 years
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 254

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 254
Study: 31942264

Group type: EXPERIMENTAL
Intervention: Fractionated lesional radiotherapy with 60 Gy in 10 fractions (given simultaneously with whole-brain helical tomotherapy with 30 Gy in 10 fractions)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Fractionated lesional radiotherapy with 60 Gy in 10 fractions
Number of subjects: 87
Study: 31942430

Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVI) of anti-VEGF (bevacizumab or ranibizumab) followed by a loose treat and extend regimen.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rescue therapy of aflibercept (Group 2).
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Initial treatment with three loading doses of either bevacizumab or ranibizumab.
Number of subjects: 63
Study: 31943126

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging with indocyanine green (ICG) administered intravenously at 0.3 mg/kg bodyweight.
Number of subjects: 173

Group type: COMPARATOR
Intervention: White-light laparoscopy alone.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Combination of white-light and NIR-ICG.
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: NIR fluorescence imaging with ICG for resection of deep infiltrating nodules.
Number of subjects: 173
Study: 31943262

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) using SF-36 mental component summary T-score
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) using SF-36 physical component summary T-score
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Fatigue using PROMIS Fatigue T-score
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Symptom burden using a 10-item Total Symptom Checklist
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Frequency of symptoms reported
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Association of APRI ≥1.50 and comorbidities with patient-reported outcomes
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Impact of Total Symptom Checklist score on regression models
Number of subjects: 876
Study: 31943691

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) use
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Aetiology
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 88
Study: 31943974

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (with dose escalation to 300 mg)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Secukinumab (any dose)
Number of subjects: 587
Study: 31945475

Group type: EXPERIMENTAL
Intervention: Baseline interrupter resistance (Rint) measurements
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator response (BDR) measurements
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Baseline Rint and sRaw in children with poorly or partially controlled asthma
Number of subjects: 130
Study: 31948386

Group type: EXPERIMENTAL
Intervention: Societal perspective
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Third party payer perspective
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Functional dependency of the person with dementia
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Educational level of the caregiver
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Caregiver's retirement status
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Quality of life in caregivers
Number of subjects: 355
Study: 31948438

Group type: EXPERIMENTAL
Intervention: Living with HIV
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Probable depression
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Hunger
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy
Number of subjects: 275
Study: 31948451

Group type: EXPERIMENTAL
Intervention: BPI-9016M (100 mg to 800 mg, QD dosing for 28 days)
Number of subjects: 20
Study: 31949011

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Number of subjects: 80
Study: 31949950

Group type: EXPERIMENTAL
Intervention: Pneumatic posterior capsulorhexis
Number of subjects: 100
Study: 31950251

Group type: EXPERIMENTAL
Intervention: Perceval sutureless bioprosthesis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall expansion > 80%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Regional underexpansion
Number of subjects: 46
Study: 31950310

Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 20
Study: 31950432

Group type: EXPERIMENTAL
Intervention: YAZ (3 mg drospirenone/20 μg ethinyl estradiol)
Number of subjects: 1921
Study: 31951027

Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GZ17-6.02 combined with 5-fluorouracil
Number of subjects: 0
Study: 31951149

Group type: EXPERIMENTAL
Intervention: Cemiplimab-rwlc
Number of subjects: 0
Study: 31951215

Group type: EXPERIMENTAL
Intervention: Quit2Heal smartphone app
Number of subjects: 59

Group type: COMPARATOR
Intervention: QuitGuide (control)
Number of subjects: 59
Study: 31951765

Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with different antigen doses and aluminum-hydroxide adjuvant
Number of subjects: 628

Group type: COMPARATOR
Intervention: RSV-PreF vaccine
Number of subjects: 628

Group type: COMPARATOR
Intervention: haNEO1-reduced vaccines
Number of subjects: 628
Study: 31952071

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 25
Study: 31952501

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Galcanezumab (both doses)
Number of subjects: 1435
Study: 31952520

Group type: EXPERIMENTAL
Intervention: Insured patients
Number of subjects: 196

Group type: COMPARATOR
Intervention: Uninsured patients
Number of subjects: 196
Study: 31952543

Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 141
Study: 31952626

Group type: EXPERIMENTAL
Intervention: Prescribed gabapentin
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Non-prescribed gabapentin
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Both prescribed and non-prescribed gabapentin
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Gabapentin use (overall)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Gabapentin use (diverted)
Number of subjects: 401
Study: 31952975

Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously over 30 min every 2 weeks for up to 96 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 78
Study: 31952983

Group type: EXPERIMENTAL
Intervention: LAD threshold of 40 mm
Number of subjects: 675
Study: 31953079

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 107
Study: 31953313

Group type: EXPERIMENTAL
Intervention: Probody therapeutic CX-072
Number of subjects: 0
Study: 31953669

Group type: EXPERIMENTAL
Intervention: Flexible bronchoscope (FB) intubation
Number of subjects: 420
Study: 31953740

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg IV
Number of subjects: 20
Study: 31953896

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 484
Study: 31953927

Group type: EXPERIMENTAL
Intervention: Elective mucosal irradiation (EMI)
Number of subjects: 46
Study: 31954100

Group type: EXPERIMENTAL
Intervention: Oral colistin and neomycin decontamination
Number of subjects: 0
Study: 31954102

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use with activity
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use at rest
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Decreasing Dlco
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Gender-Age-Lung Physiology score
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Composite Physiologic Index scores
Number of subjects: 829
Study: 31954144

Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Television use
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: Video gaming
Number of subjects: 3612
Study: 31954227

Group type: EXPERIMENTAL
Intervention: Symptom Navi© Programme (SN©P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse training for SN©P
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work-related Sense of Coherence (Work-SoC) scale
Number of subjects: 0
Study: 31954624

Group type: EXPERIMENTAL
Intervention: Nazartinib (EGF816) 150 mg once daily (tablet)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nazartinib (EGF816)
Number of subjects: 180
Study: 31954643

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Left Bundle Branch Block (LBBB)
Number of subjects: 24
Study: 31954661

Group type: EXPERIMENTAL
Intervention: Ultrathin strut bioresorbable polymer sirolimus-eluting stent (BP SES)
Number of subjects: 1000000

Group type: COMPARATOR
Intervention: Thin strut durable polymer everolimus-eluting stent (DP EES)
Number of subjects: 1000000
Study: 31954677

Group type: EXPERIMENTAL
Intervention: Transcatheter leak closure with detachable coils
Number of subjects: 30
Study: 31955915

Group type: EXPERIMENTAL
Intervention: Differential threat conditioning and extinction paradigm
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Skin conductance response to conditioned (CS+, CS-) and unconditioned threat stimuli
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Skin conductance response
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Unconditioned responding
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Anticipatory responding to potential threat
Number of subjects: 351
Study: 31956341

Group type: EXPERIMENTAL
Intervention: Diabetic foot ulcer treatment
Number of subjects: 129
Study: 31956422

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1071
Study: 31956421

Group type: EXPERIMENTAL
Intervention: Dynamic LED lighting for 4 weeks in addition to standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static LED lighting for 4 weeks in addition to standard treatment
Number of subjects: 0
Study: 31956433

Group type: EXPERIMENTAL
Intervention: Real long-wave diathermy (LWD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham long-wave diathermy (sham LWD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual massage
Number of subjects: 0
Study: 31956432

Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept (IVZ) 1.25 mg
Number of subjects: 21
Study: 31956723

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31956726

Group type: EXPERIMENTAL
Intervention: Heated Tobacco Products (HTPs)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Electronic Cigarettes (ECs)
Number of subjects: 220
Study: 31956893

Group type: EXPERIMENTAL
Intervention: Frailty (≥3 domains present)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Prefrail (1-2 domains present)
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Robust (0 domains present)
Number of subjects: 1148
Study: 31956961

Group type: EXPERIMENTAL
Intervention: 20 mg tofogliflozin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5 mg glimepiride
Number of subjects: 40
Study: 31957634

Group type: EXPERIMENTAL
Intervention: E-CABG DSWI score (risk score for deep sternal wound infection)
Number of subjects: 7352

Group type: EXPERIMENTAL
Intervention: E-CABG DSWI score
Number of subjects: 7352
Study: 31957639

Group type: EXPERIMENTAL
Intervention: Patients with DOA
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 104
Study: 31958096

Group type: EXPERIMENTAL
Intervention: DA-CH5
Number of subjects: 0
Study: 31958302

Group type: EXPERIMENTAL
Intervention: NGT-1-hour-high (glucose ≥8.6 mmol/L)
Number of subjects: 434

Group type: COMPARATOR
Intervention: NGT-1-hour-normal (glucose <8.6 mmol/L)
Number of subjects: 434

Group type: COMPARATOR
Intervention: NGT group
Number of subjects: 434

Group type: COMPARATOR
Intervention: Pre-diabetes group
Number of subjects: 434

Group type: COMPARATOR
Intervention: Diabetes group
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: One-hour glucose concentration ≥8.6 mmol/L
Number of subjects: 434
Study: 31958308

Group type: EXPERIMENTAL
Intervention: 14 BGMS (including ABRA, Accu-Chek Guide, AURUM, etc.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 BGMS (including ABRA, Accu-Chek Guide, AURUM, etc.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All tested BGMS
Number of subjects: 100
Study: 31958310

Group type: EXPERIMENTAL
Intervention: Dynamic change in fetuin-A levels from the first to the second trimester
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Highest quartile of the increase in fetuin-A concentration from the first to the second trimester
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Change in fetuin-A concentration
Number of subjects: 270
Study: 31958884

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 174
Study: 31959034

Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels >14 ng/L at anthracycline completion
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase
Number of subjects: 323
Study: 31959059

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 120

Group type: COMPARATOR
Intervention: High ligation and stripping
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 120
Study: 31959135

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Model
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Perceived stress and cognitive function
Number of subjects: 429
Study: 31959168

Group type: EXPERIMENTAL
Intervention: Patients not considering pain as a warning signal (43.2% had a favourable functional improvement of ≥30% on the RMDQ)
Number of subjects: 816

Group type: COMPARATOR
Intervention: Patients considering pain a warning signal (41.2% had a favourable functional improvement of ≥30% on the RMDQ)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: STarT Back Tool high-risk patients
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Beliefs about finding the cause, diagnostic imaging, perceiving to have received advice to stay active, or pain intensity
Number of subjects: 816
Study: 31959169

Group type: EXPERIMENTAL
Intervention: PC-PA quadrant affiliation
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: PC-PA quadrants characterization
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Clinical characteristics assessment
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Assessment of physical activity (PA)
Number of subjects: 283
Study: 31959346

Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg twice daily
Number of subjects: 118
Study: 31959428

Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 BE-THV with severe LZC
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Balloon predilatation (BPreD) in patients with severe LZC
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Severe LVOTC
Number of subjects: 350
Study: 31959583

Group type: EXPERIMENTAL
Intervention: Subjective social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived stressfulness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative coping style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived stressfulness mediating effect
Number of subjects: 0